Marsh K


439 results

Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection.Hodgson SH, Llewellyn D, Silk SE, Milne KH, Elias SC, Miura K, Kamuyu G, Juma EA, Magiri C, Muia A, Jin J, Spencer AJ, Longley RJ, Mercier T, Decosterd L, Long CA, Osier FH, Hoffman SL, Ogutu B, Hill AV, Marsh K, Draper SJ
Front Microbiol, (2016). 7:1604

The effect of declining exposure on T cell-mediated immunity to Plasmodium falciparum - an epidemiological "natural experiment".Bediako Y, Ngoi JM, Nyangweso G, Wambua J, Opiyo M, Nduati EW, Bejon P, Marsh K, Ndungu FM
BMC Med, (2016). 14:143

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M, Kaslow DC, Njuguna P, Marsh K, Bejon P
N Engl J Med, (2016). 374:2519-29

Age, Spatial, and Temporal Variations in Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational Study.Mogeni P, Williams TN, Fegan G, Nyundo C, Bauni E, Mwai K, Omedo I, Njuguna P, Newton CR, Osier F, Berkley JA, Hammitt LL, Lowe B, Mwambingu G, Awuondo K, Mturi N, Peshu N, Snow RW, Noor A, Marsh K, Bejon P
PLoS Med, (2016). 13:e1002047

A single point in protein trafficking by Plasmodium falciparum determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies.Chan JA, Howell KB, Langer C, Maier AG, Hasang W, Rogerson SJ, Petter M, Chesson J, Stanisic DI, Duffy MF, Cooke BM, Siba PM, Mueller I, Bull PC, Marsh K, Fowkes FJ, Beeson JG
Cell Mol Life Sci, (2016). 73:4141-58

Comparison of allele frequencies of Plasmodium falciparum merozoite antigens in malaria infections sampled in different years in a Kenyan population.Ochola-Oyier LI, Okombo J, Wagatua N, Ochieng J, Tetteh KK, Fegan G, Bejon P, Marsh K
Malar J, (2016). 15:261

Malaria hotspots defined by clinical malaria, asymptomatic carriage, PCR and vector numbers in a low transmission area on the Kenyan Coast.Kangoye DT, Noor A, Midega J, Mwongeli J, Mkabili D, Mogeni P, Kerubo C, Akoo P, Mwangangi J, Drakeley C, Marsh K, Bejon P, Njuguna P
Malar J, (2016). 15:213

Serological Conservation of Parasite-Infected Erythrocytes Predicts Plasmodium falciparum Erythrocyte Membrane Protein 1 Gene Expression but Not Severity of Childhood Malaria.Warimwe GM, Abdi AI, Muthui M, Fegan G, Musyoki JN, Marsh K, Bull PC
Infect Immun, (2016). 84:1331-1335

Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children.Murungi LM, Sonden K, Llewellyn D, Rono J, Guleid F, Williams AR, Ogada E, Thairu A, Farnert A, Marsh K, Draper SJ, Osier FHA
Infect Immun, (2016). 84:950-963

A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens.Tan J, Pieper K, Piccoli L, Abdi A, Perez MF, Geiger R, Tully CM, Jarrossay D, Maina Ndungu F, Wambua J, Bejon P, Fregni CS, Fernandez-Rodriguez B, Barbieri S, Bianchi S, Marsh K, Thathy V, Corti D, Sallusto F, Bull P, Lanzavecchia A
Nature, (2016). 529:105-109

Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity.Kangoye DT, Mensah VA, Murungi LM, Nkumama I, Nebie I, Marsh K, Cisse B, Bejon P, Osier FH, Sirima SB, MVVC Infant Immunology Study Group
Vaccine, (2016). 34:160-6

Malaria and Age Variably but Critically Control Hepcidin Throughout Childhood in Kenya.Atkinson SH, Uyoga SM, Armitage AE, Khandwala S, Mugyenyi CK, Bejon P, Marsh K, Beeson JG, Prentice AM, Drakesmith H, Williams TN
EBioMedicine, (2015). 2:1478-86

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, Lievens M, Abdulla S, Adjei S, Agbenyega T, Agnandji ST, Aide P, Anderson S, Ansong D, Aponte JJ, Asante KP, Bejon P, Birkett AJ, Bruls M, Connolly KM, D'Alessandro U, Dobano C, Gesase S, Greenwood B, Grimsby J, Tinto H, Hamel MJ, Hoffman I, Kamthunzi P, Kariuki S, Kremsner PG, Leach A, Lell B, Lennon NJ, Lusingu J, Marsh K, Martinson F, Molel JT, Moss EL, Njuguna P, Ockenhouse CF, Ogutu BR, Otieno W, Otieno L, Otieno K, Owusu-Agyei S, Park DJ, Pelle K, Robbins D, Russ C, Ryan EM, Sacarlal J, Sogoloff B, Sorgho H, Tanner M, Theander T, Valea I, Volkman SK, Yu Q, Lapierre D, Birren BW, Gilbert PB, Wirth DF
N Engl J Med, (2015). 373:2025-2037

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, Drakeley C, Gesase S, Lusingu J, Ansong D, Adjei S, Agbenyega T, Ogutu B, Otieno L, Otieno W, Agnandji ST, Lell B, Kremsner P, Hoffman I, Martinson F, Kamthunzu P, Tinto H, Valea I, Sorgho H, Oneko M, Otieno K, Hamel MJ, Salim N, Mtoro A, Abdulla S, Aide P, Sacarlal J, Aponte JJ, Njuguna P, Marsh K, Bejon P, Riley EM, Ghani AC
Lancet Infect Dis, (2015). 15:1450-8

Genetic determinants of anti-malarial acquired immunity in a large multi-centre study.Shelton JM, Corran P, Risley P, Silva N, Hubbart C, Jeffreys A, Rowlands K, Craik R, Cornelius V, Hensmann M, Molloy S, Sepulveda N, Clark TG, Band G, Clarke GM, Spencer CC, Kerasidou A, Campino S, Auburn S, Tall A, Ly AB, Mercereau-Puijalon O, Sakuntabhai A, Djimde A, Maiga B, Toure O, Doumbo OK, Dolo A, Troye-Blomberg M, Mangano VD, Verra F, Modiano D, Bougouma E, Sirima SB, Ibrahim M, Hussain A, Eid N, Elzein A, Mohammed H, Elhassan A, Elhassan I, Williams TN, Ndila C, Macharia A, Marsh K, Manjurano A, Reyburn H, Lemnge M, Ishengoma D, Carter R, Karunaweera N, Fernando D, Dewasurendra R, Drakeley CJ, Riley EM, Kwiatkowski DP, Rockett KA, Malaria GENConsortium
Malar J, (2015). 14:333

Identifying children with excess malaria episodes after adjusting for variation in exposure: identification from a longitudinal study using statistical count models.Ndungu FM, Marsh K, Fegan G, Wambua J, Nyangweso G, Ogada E, Mwangi T, Nyundo C, Macharia A, Uyoga S, Williams TN, Bejon P
BMC Med, (2015). 13:183

Malaria eradication and elimination: views on how to translate a vision into reality.Tanner M, Greenwood B, Whitty CJ, Ansah EK, Price RN, Dondorp AM, von Seidlein L, Baird JK, Beeson JG, Fowkes FJ, Hemingway J, Marsh K, Osier F
BMC Med, (2015). 13:167

Multiple clinical episodes of Plasmodium falciparum malaria in a low transmission intensity setting: exposure versus immunity.Rono J, Farnert A, Murungi L, Ojal J, Kamuyu G, Guleid F, Nyangweso G, Wambua J, Kitsao B, Olotu A, Marsh K, Osier FH
BMC Med, (2015). 13:114

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, Bliss C, Hodgson SH, Njuguna P, Viebig NK, Nicosia A, Gitau E, Douglas S, Illingworth J, Marsh K, Lawrie A, Imoukhuede EB, Ewer K, Urban BC, Hill AVS, Bejon P, Mvvc group
Sci Transl Med, (2015). 7:286re5

Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya.Hodgson SH, Juma E, Salim A, Magiri C, Njenga D, Molyneux S, Njuguna P, Awuondo K, Lowe B, Billingsley PF, Cole AO, Ogwang C, Osier F, Chilengi R, Hoffman SL, Draper SJ, Ogutu B, Marsh K
Malar J, (2015). 14:182